United Therapeutics Corporation
Could not find a ticker for this position, may be a filing error
A maker of medicines for rare lung conditions such as pulmonary arterial hypertension, sold under brands like Remodulin and Tyvaso. Founder Martine Rothblatt launched the company in 1996 after her young daughter was diagnosed with the disease, turning a personal fight into a career. The firm is also known for a futuristic goal: gene-edited pig organs for human transplants, an approach that has made it a familiar name in xenotransplantation.
1.00% Convertible Senior Notes due 2016-09-15 (Rule 144A)
Granted 2.96M · Sold 2.91M
Granted 809.9K · Sold 698.4K
Granted 1.01M · Sold 817.2K
Granted 67.1K · Sold 24.5K
Granted 589.3K · Sold 556.0K
Granted 51.9K · Sold 13.0K
Granted 68.4K · Sold 19.9K
Granted 11.8K
Granted 44.1K · Sold 52.7K
Granted 3.5K · Sold 5.1K
Granted 61.9K · Sold 17.2K
Granted 46.5K · Sold 43.8K
Granted 48.9K · Sold 44.7K
Granted 47.2K · Sold 27.3K
Granted 2.0K · Sold 2.0K
Granted 1.2K · Sold 1.1K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Rothblatt Martine AChairperson & CEO, Director · 3153 transactions | — | 49.6K | 2.96M | — | 2.91M |
| Mahon Paul AEVP & GENERAL COUNSEL · 577 transactions | +23.9% | 45.2K | 809.9K | — | 698.4K |
| Benkowitz MichaelPRESIDENT AND COO · 649 transactions | — | 36.5K | 1.01M | — | 817.2K |
| Thompson Tommy GDirector · 60 transactions | — | 30.3K | 67.1K | — | 24.5K |
| Edgemond JamesCFO AND TREASURER · 539 transactions | +1975.3% | 25.5K | 589.3K | — | 556.0K |
| Giltner RichardDirector · 17 transactions | +75.7% | 20.6Kas of Jul 2025 | 51.9K | — | 13.0K |
| Kurzweil RayDirector · 20 transactions | +90.7% | 17.6K | 68.4K | — | 19.9K |
| Klein Katherine JDirector · 4 transactions | +699.5% | 13.4Kas of Mar 2024 | 11.8K | — | — |
| Sullivan Louis WDirector · 55 transactions | — | 6.4K | 44.1K | — | 52.7K |
| Mesa NildaDirector · 17 transactions | -24.3% | 5.0K | 3.5K | — | 5.1K |
| Dwek RaymondDirector · 46 transactions | — | 4.8Kas of Apr 2025 | 61.9K | — | 17.2K |
| Olian Judy D.Director · 34 transactions | -53.6% | 4.2K | 46.5K | — | 43.8K |
| Causey ChristopherDirector · 55 transactions | +458.7% | 4.2K | 48.9K | — | 44.7K |
| Patusky ChristopherDirector · 58 transactions | — | 2.6K | 47.2K | — | 27.3K |
| Maxwell LindaDirector · 2 transactions | — | 2.0Kas of May 2022 | 2.0K | — | 2.0K |
| Malcolm JanDirector · 11 transactions | — | 125 | 1.2K | — | 1.1K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -5.24M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.